AU2005209473B2 - Polymorphic forms of a GABAA agonist - Google Patents

Polymorphic forms of a GABAA agonist Download PDF

Info

Publication number
AU2005209473B2
AU2005209473B2 AU2005209473A AU2005209473A AU2005209473B2 AU 2005209473 B2 AU2005209473 B2 AU 2005209473B2 AU 2005209473 A AU2005209473 A AU 2005209473A AU 2005209473 A AU2005209473 A AU 2005209473A AU 2005209473 B2 AU2005209473 B2 AU 2005209473B2
Authority
AU
Australia
Prior art keywords
gaboxadol
crystalline
peak
monohydrate
anhydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005209473A
Other languages
English (en)
Other versions
AU2005209473A1 (en
Inventor
Vincent Brett Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31971783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005209473(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Publication of AU2005209473A1 publication Critical patent/AU2005209473A1/en
Assigned to H. LUNDBECK A/S reassignment H. LUNDBECK A/S Request for Assignment Assignors: MERCK SHARP & DOHME LIMITED
Application granted granted Critical
Publication of AU2005209473B2 publication Critical patent/AU2005209473B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2005209473A 2004-01-30 2005-01-28 Polymorphic forms of a GABAA agonist Ceased AU2005209473B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0402118.4 2004-01-30
GBGB0402118.4A GB0402118D0 (en) 2004-01-30 2004-01-30 Polymorphic forms of a GABAA agonist
PCT/GB2005/000288 WO2005073237A2 (en) 2004-01-30 2005-01-28 Polymorphic forms of a gabaa agonist

Publications (2)

Publication Number Publication Date
AU2005209473A1 AU2005209473A1 (en) 2005-08-11
AU2005209473B2 true AU2005209473B2 (en) 2010-03-04

Family

ID=31971783

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005209473A Ceased AU2005209473B2 (en) 2004-01-30 2005-01-28 Polymorphic forms of a GABAA agonist

Country Status (34)

Country Link
US (2) US7262300B2 (https=)
EP (2) EP2042505A1 (https=)
JP (1) JP4917440B2 (https=)
KR (1) KR101210361B1 (https=)
CN (1) CN1914212B (https=)
AR (1) AR047511A1 (https=)
AT (1) ATE414088T1 (https=)
AU (1) AU2005209473B2 (https=)
BR (1) BRPI0506858A (https=)
CA (1) CA2554536C (https=)
CO (1) CO5700743A2 (https=)
CY (1) CY1108647T1 (https=)
DE (1) DE602005010975D1 (https=)
DK (1) DK1713813T3 (https=)
DO (1) DOP2005000013A (https=)
EA (1) EA009413B1 (https=)
EC (1) ECSP066735A (https=)
ES (1) ES2314613T3 (https=)
GB (2) GB0402118D0 (https=)
HR (1) HRP20080614T3 (https=)
IL (1) IL176863A0 (https=)
MA (1) MA28364A1 (https=)
MX (1) MXPA06008595A (https=)
MY (1) MY139525A (https=)
NO (1) NO20063843L (https=)
NZ (1) NZ548191A (https=)
PE (1) PE20050769A1 (https=)
PL (1) PL1713813T3 (https=)
PT (1) PT1713813E (https=)
SI (1) SI1713813T1 (https=)
TW (1) TWI345972B (https=)
UA (1) UA87487C2 (https=)
WO (1) WO2005073237A2 (https=)
ZA (1) ZA200605307B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
KR101271263B1 (ko) 2005-09-28 2013-06-07 아우리스 메디칼 아게 내이 장애 치료용 약학 조성물
CN102093387B (zh) * 2009-12-10 2012-07-25 天津泰普医药知识产权流转储备中心有限公司 4,5,6,7-四氢异噁唑并[5,4-c]吡啶-3-醇一水合物的晶型化合物
WO2013087090A1 (en) 2011-12-12 2013-06-20 Auris Medical Ag Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
EP4541420A3 (en) 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
WO2020061410A1 (en) 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
JP2022514194A (ja) 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112786A2 (en) * 2003-06-25 2004-12-29 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4315934A (en) 1979-09-24 1982-02-16 Sandoz Ltd. Organic compounds
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4352731A (en) * 1980-11-03 1982-10-05 Occidental Research Corporation Apparatus for selective wetting of particles
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
EP1220658A1 (en) 1999-09-28 2002-07-10 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
BR0209820A (pt) 2001-05-18 2004-06-01 Lonza Ag Processo para a preparação de formulações sólidas de 3-hidróxi-3-metilbutirato de sódio
AU2002338855B2 (en) 2001-05-21 2007-08-16 H. Lundbeck A/S Granular preparations of gaboxadol
WO2004022550A1 (en) * 2002-09-03 2004-03-18 Naturon Limited Compound for treatment of anxiety and methods of preparation and use thereof
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
AR045540A1 (es) * 2003-09-05 2005-11-02 Lundbeck & Co As H Metodo de elaboracion de 4,5,6,7 tetrahidroisoxazol [5,4-c] piridin-3-ol (thip)
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
MXPA06015196A (es) 2004-06-29 2007-03-15 Lundbeck & Co As H Tratamiento del dolor neuropatico, la fibromialgia o la artritis reumatoide.
GB0417558D0 (en) 2004-08-06 2004-09-08 Merck Sharp & Dohme Novel combination therapy
EP1848420A4 (en) 2005-01-28 2008-01-23 Merck & Co Inc POLYMORPH SHAPES OF A GABAA AGONIST
WO2006102093A1 (en) 2005-03-18 2006-09-28 Transform Pharmaceuticals, Inc. Gaboxadol forms, compositions thereof, and related methods
US20080262029A1 (en) 2005-04-29 2008-10-23 H. Lundbeck A/S Acid and Base Salt Forms of Gaboxadol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004112786A2 (en) * 2003-06-25 2004-12-29 H. Lundbeck A/S Gaboxadol for treating depression and other affective disorders

Also Published As

Publication number Publication date
US8236958B2 (en) 2012-08-07
GB2410434A (en) 2005-08-03
CO5700743A2 (es) 2006-11-30
DK1713813T3 (da) 2009-02-16
GB0402118D0 (en) 2004-03-03
AR047511A1 (es) 2006-01-25
TWI345972B (en) 2011-08-01
IL176863A0 (en) 2006-10-31
WO2005073237A3 (en) 2005-10-20
CY1108647T1 (el) 2014-04-09
PE20050769A1 (es) 2005-10-04
UA87487C2 (ru) 2009-07-27
KR20070007070A (ko) 2007-01-12
EP1713813B1 (en) 2008-11-12
CN1914212A (zh) 2007-02-14
AU2005209473A1 (en) 2005-08-11
EP1713813A2 (en) 2006-10-25
JP4917440B2 (ja) 2012-04-18
ATE414088T1 (de) 2008-11-15
GB0501847D0 (en) 2005-03-09
MXPA06008595A (es) 2006-08-28
CA2554536A1 (en) 2005-08-11
ZA200605307B (en) 2007-11-28
MA28364A1 (fr) 2006-12-01
TW200534856A (en) 2005-11-01
SI1713813T1 (sl) 2009-02-28
DE602005010975D1 (de) 2008-12-24
HK1096547A1 (en) 2007-06-01
ES2314613T3 (es) 2009-03-16
KR101210361B1 (ko) 2012-12-10
WO2005073237A2 (en) 2005-08-11
HRP20080614T3 (en) 2009-01-31
US20070259912A1 (en) 2007-11-08
US20050171142A1 (en) 2005-08-04
EA009413B1 (ru) 2007-12-28
CN1914212B (zh) 2010-10-06
ECSP066735A (es) 2006-10-31
US7262300B2 (en) 2007-08-28
PL1713813T3 (pl) 2009-04-30
JP2007519697A (ja) 2007-07-19
NZ548191A (en) 2010-04-30
EA200601404A1 (ru) 2006-12-29
EP2042505A1 (en) 2009-04-01
PT1713813E (pt) 2008-12-26
MY139525A (en) 2009-10-30
CA2554536C (en) 2012-09-18
DOP2005000013A (es) 2005-08-15
NO20063843L (no) 2006-08-29
BRPI0506858A (pt) 2007-05-29

Similar Documents

Publication Publication Date Title
US8236958B2 (en) Polymorphic forms of a GABAA agonist
HK1211587A1 (en) Process for purifying staurosporine
US8193216B2 (en) Polymorphic forms of a GABAA agonist
WO2018109786A1 (en) Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
US20030191347A1 (en) Venlafaxine base
WO2000029383A1 (en) Crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide
HK1096547B (en) Polymorphic forms of a gabaa agonist
HUT77907A (hu) 2-Metil-4-(4-metil-piperazino)-1OH-tieno[2,3-b][1,5] benzodiazepin alkalmazása kognitiv diszfunkció kezelésére gyógyszerkészítmények előállítására
EP0864572B1 (en) Crystal of hydrate and process for preparation thereof
WO2014023027A1 (zh) 盐酸埃罗替尼多晶型物及其制备方法
WO2008095964A1 (en) Crystalline form of moxifloxacin base
JP2002507215A (ja) ５−（２−エチル−２ｈ−テトラゾール−５−イル）−１−メチル−１，２，３，６−テトラヒドロピリジン マレイン酸塩
HK1149754A (en) Process for purifying staurosporine

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: H. LUNDBECK A/S

Free format text: FORMER APPLICANT(S): MERCK SHARP & DOHME LIMITED

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired